Acute bilateral endophthalmitis following bilateral intravitreal bevacizumab (avastin) injection

Middle East African Journal of Ophthalmology

Volumn 20, Issue 1, 2013, Pages 87-88

  Tabatabaii, Ali ^a   Ahmadraji, Aliasghar ^a   Khodabande, Alireza ^a   Mansouri, Mohammadreza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bevacizumab; Endophthalmitis; Intravitreal Injection

Indexed keywords

BEVACIZUMAB; CEFTAZIDIME; VANCOMYCIN;

ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; B SCAN; BACTERIUM CULTURE; CASE REPORT; CLINICAL FEATURE; DIABETIC MACULAR EDEMA; ENDOPHTHALMITIS; EYE PAIN; FEMALE; HUMAN; HYPOPYON; PARS PLANA VITRECTOMY; PHOTOPHOBIA; PRIORITY JOURNAL; RETINA NECROSIS; STAPHYLOCOCCUS EPIDERMIDIS; SYMPTOM; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS BODY; VITREOUS OPACITY; VITRITIS;

BEVACIZUMAB; ENDOPHTHALMITIS; INTRAVITREAL INJECTION;

ACUTE DISEASE; AGED; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CEFTAZIDIME; DRUG THERAPY, COMBINATION; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84878786850     PISSN: 09749233     EISSN: 09751599     Source Type: Journal    
DOI: 10.4103/0974-9233.106402     Document Type: Article

References (9)

1. CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
2. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400.
3. Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F. Infections and noninfections endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007;23:240-2.
4. Mason JO 3rd, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, et al. Incidence of acute onset endophthalmitis following interavitreal bevacizumab (avastin) injection. Retina 2008;28:564-7.
5. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-9.
6. Arturay O, Yzbasioglu E, Rasier R, Sengul A. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond) 2009;23:2187-93.
7. Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Piña Y, Decatur CL, et al. Intravitreal injection analysis at the Bascom Palmer Eye Institute: Evaluation of clinical indications for the treatment and incidence rates of endophthalmitis. Clin Ophthalmol 2010;4:519-24.
8. Stewart JM, Srivastava SK, Fung AE, Mahmoud TH, Telander DG, Hariprasad SM, et al. Bacterial contamination of needles used for intravitreal injections: A prospective, multicenter study. Ocul Immunol Inflamm 2011;19:32-8.
9. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn't blind people, people blind people. Am J Ophthalmol 2012;153:196-203.